A Study of Escalating Doses of Itacitinib Administered Orally in Patients With Plaque Psoriasis

Completed · Phase 2 · Has a placebo group

Conditions studied: Plaque Psoriasis

In brief

This is a study of itacitinib in patients with chronic plaque psoriasis. This study will evaluate safety and efficacy parameters of itacitinib.

Key facts

Study ID

NCT01634087

Run by

Incyte Corporation

People needed

50

Starts

2012-06-01

Expected to finish

2013-02-01

Last updated by the study team

2019-03-12

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects with chronic plaque psoriasis aged 18 to 75 who have had insufficient response to topical agents, and who meet the psoriasis assessment expectations as defined in the study protocol

You may not qualify if…

• Females who are pregnant or breastfeeding
• Men and women who cannot comply with requirements to avoid fathering a child or becoming pregnant, respectively
• Subjects treated with leflunomide or other biological therapies to treat psoriasis and all JAK-STAT inhibitors within 12 weeks prior to first dose of study drug

Where it is running

• Study site — Hot Springs, Arkansas, United States
• Study site — Los Angeles, California, United States
• Study site — Clinton, Minnesota, United States
• Study site — Fridley, Minnesota, United States
• Study site — Rochester, New York, United States
• Study site — Moncton, New Brunswick, Canada
• Study site — Windsor, Ontario, Canada
• Study site — Montreal, Quebec, Canada
• Study site — Québec, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.